We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$8.89B
AUM Growth
+$1.45B
Cap. Flow
+$1.09B
Cap. Flow %
12.29%
Top 10 Hldgs %
26.12%
Holding
266
New
39
Increased
114
Reduced
52
Closed
27

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$63.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$50M
3
VR
Validus Hold Ltd
VR
+$44.1M
4
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.4M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$59.3M
2
DHR icon
Danaher
DHR
+$44.2M
3
HOLX
Hologic
HOLX
+$42M
4
BDX icon
Becton Dickinson
BDX
+$40.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$38.7M

Sector Composition

Rank Sector Weight
1 Financials 21.97%
2 Healthcare 21.33%
3 Technology 19.13%
4 Communication Services 9.13%
5 Industrials 6.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
226
argenx
ARGX
$57.4B
$1.12M 0.01%
+50,000
New +$1.04M
ADAP
227
DELISTED
Adaptimmune Therapeutics
ADAP
$819K 0.01%
+100,000
New +$624K
ESV
228
DELISTED
Ensco Rowan plc
ESV
$635K 0.01%
26,610
– –
KVHI icon
229
KVH Industries
KVHI
$177M
$581K 0.01%
+48,600
New +$530K
BKD icon
230
Brookdale Senior Living
BKD
$3.62B
– –
-60,000
Closed -$883K
DXCM icon
231
DexCom
DXCM
$27.6B
– –
-160,400
Closed -$2.93M
EVH icon
232
Evolent Health
EVH
$475M
– –
-171,281
Closed -$4.34M
EW icon
233
Edwards Lifesciences
EW
$47.6B
– –
-690,000
Closed -$27.2M
GILD icon
234
Gilead Sciences
GILD
$161B
– –
-85,000
Closed -$6.02M
HOLX
235
DELISTED
Hologic
HOLX
– –
-925,940
Closed -$42M
IMAX icon
236
IMAX
IMAX
$2.38B
– –
-85,412
Closed -$1.88M
INGN icon
237
Inogen
INGN
$167M
– –
-106,474
Closed -$10.2M
INTC icon
238
Intel
INTC
$466B
– –
-227,660
Closed -$7.68M
KLAC icon
239
KLA
KLAC
$275B
– –
-754,780
Closed -$6.91M
LLY icon
240
Eli Lilly
LLY
$1.07T
– –
-400,000
Closed -$32.9M
NGNE icon
241
Neurogene
NGNE
$696M
– –
-2,500
Closed -$704K
PANW icon
242
Palo Alto Networks
PANW
$264B
– –
-124,200
Closed -$2.77M
PCTY icon
243
Paylocity
PCTY
$6.71B
– –
-64,523
Closed -$2.92M
POWI icon
244
Power Integrations
POWI
$3.54B
– –
-46,858
Closed -$1.71M
WCN
245
Waste Connections
WCN
$42.8B
– –
-154,769
Closed -$9.97M
ICPT
246
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-60,000
Closed -$7.26M
NUVA
247
DELISTED
NuVasive, Inc.
NUVA
– –
-350,000
Closed -$26.9M
VIVO
248
DELISTED
Meridian Bioscience Inc
VIVO
– –
-44,600
Closed -$700K
DERM
249
DELISTED
Dermira, Inc.
DERM
– –
-100,000
Closed -$2.91M
ONCE
250
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-15,000
Closed -$896K
7 8 9
10
11

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Polar Capital held 266 positions worth $8.89B, up 20% from $7.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Polar Capital deployed $1.09B of net new capital in Q3 2017, opening 39 new positions and adding to 114 existing holdings. Its largest new stake was Puma Biotechnology: 360,000 shares worth $43.1M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Medtronic, an estimated $59.3M trimmed.

  • Polar Capital's largest Q3 2017 buy was Puma Biotechnology: 360,000 shares worth $43.1M.
  • Polar Capital added most to Amgen in Q3 2017, an estimated $63.8M increase.
  • Polar Capital's biggest Q3 2017 reduction was Medtronic, cutting an estimated $59.3M.
  • Polar Capital fully exited Hologic in Q3 2017, selling an estimated $42M.
  • Polar Capital's ten largest holdings make up 26% of its $8.89B portfolio in Q3 2017.
  • Polar Capital opened 39 new positions and closed 27 in Q3 2017.
  • Polar Capital's portfolio value rose 20% quarter-over-quarter to $8.89B.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.